NCT05026983 2026-04-16Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesM.D. Anderson Cancer CenterPhase 2 Recruiting35 enrolled
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT04657991 2026-04-07A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaPfizerPhase 3 Active not recruiting257 enrolled
NCT04221438 2026-04-01Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementEastern Cooperative Oncology GroupPhase 2 Terminated3 enrolled 11 charts
NCT05355701 2026-03-27A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.PfizerPhase 1 Recruiting267 enrolled